- Status Complete
- Type New application
- Pre-PASC consultation Not applicable
- Pre-MSAC consultation Closed
- Outcome Deferred
Application details
Reason for application
The Sixth Community Pharmacy Agreement provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacists role in delivering primary health care services.
The outcomes of all PTP Trials will undergo an independent Health Technology Assessment (HTA) to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.
Information on the PTP is available on the Department of Health website.
Service or technology in this application
The Pharmacy Diabetes Screening Trial compared three different pharmacy-based screening models:
- Risk assessment using a validated tool (AUSDRISK) alone (group A)
- AUSDRISK followed by point-of-care glycated haemoglobin (group B)
- AUSDRISK followed by point-of-care blood glucose testing (group C)
Type: Investigative
Medical condition this application addresses
Diabetes mellitus is a chronic disorder that reduces the body’s ability to produce and/or use insulin (a hormone produced by the pancreas to regulate blood sugar levels). This results in high blood sugar levels, which lead to serious complications such as stroke; diabetes-related eye disease such as diabetic retinopathy; heart disease; high blood pressure; kidney disease; vascular disease; nerve damage; and foot problems.
Application documents
Executive summary
Consultation survey
Public summary document
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Meetings to consider this application
- PASC meeting: Not applicable
- ESC meeting: 7 to 8 October 2021
- MSAC meeting: 25 to 26 November 2021